Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2

Clinical Cancer Research

Volumn 14, Issue 21, 2008, Pages 6790-6796

  Ougolkov, Andrei V ^a   Bilim, Vladimir N ^b   Billadeau, Daniel D ^a,c  

^a Mayo Clinic   (United States)

^b YAMAGATA UNIVERSITY   (Japan)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; DOXORUBICIN; ENHANCER OF ZESTE HOMOLOGUE 2; GEMCITABINE; HISTONE METHYLTRANSFERASE; UNCLASSIFIED DRUG; CDKN1B PROTEIN, HUMAN; DNA BINDING PROTEIN; EZH2 PROTEIN, HUMAN; PROTEIN METHYLTRANSFERASE; SIGNAL PEPTIDE; TRANSCRIPTION FACTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CYTOSOLIC FRACTION; DRUG SENSITIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADENOCARCINOMA; CELL NUCLEUS; DRUG RESISTANCE; ENZYMOLOGY; METABOLISM; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PANCREATIC NEOPLASMS; PROTEIN METHYLTRANSFERASES; TRANSCRIPTION FACTORS;

EID: 58149214373     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1013     Document Type: Article

References (31)

1. Jaffee EM, Hruban RH, Canto M, Kern SE. Focus on pancreas cancer. Cancer Cell 2002;2:25-8.
2. Santos-Rosa H, Caldas C. Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer 2005;41:2381-402.
3. Cao R, Wang L, Wang H, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002;298:1039-43.
4. Viré E, Brenner C, Deplus R, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006;439:871-4.
5. Cardoso C, Mignon C, Hetet G, Grandchamps B, Fontes M, Colleaux L. The human EZH2 gene: genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders. Eur J Hum Genet 2000;8:174-80.
6. Visser HP, Gunster MJ, Kluin-Nelemans HC, et al. The Polycomb group protein EZH2 is up-regulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol 2001;112:950-8.
7. Abbosh PH, Montgomery JS, Starkey JA, et al. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells. Cancer Res 2006;66:5582-91.
8. Fujii S, Ochiai A. Enhancer of zeste homolog 2 down-regulates E-cadherin by mediating histone H3 methylation in gastric cancer cells. Cancer Sci 2008;99:738-46.
9. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-9.
10. Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 2003;100:11606-11.
11. Zakaria S, Gomes TS, Savoy DN, et al. Differential regulation of TCR-mediated gene transcription by Vav family members. J Exp Med 2004;199:429-34.
12. Ougolkov A, Zhang B, Yamashita K, et al. Associations among β-TrCP, an E3 ubiquitin ligase receptor, β-catenin, and NF-κB in colorectal cancer. J Natl Cancer Inst 2004;96:1161-70.
13. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, and Billadeau DD. Glycogen synthase kinase-3β participates in nuclear factor-κB- mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 2005;65:2076-81.
14. Dignam JD, Lebovitz RM, and Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983;11:1475-89.
15. Loda M, Cukor B, Tam S, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231-4.
16. Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-5.
17. van der Vlag J, Otte AP. Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat Genet 1999;23:474-8.
18. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 2006;6:846-56.
19. Kollmannsberger C, Peters HD, Fink U. Chemotherapy in advanced pancreatic adenocarcinoma. Cancer Treat Rev 1998;24:133-56.
20. Casper ES, Kelsen DP. Adenocarcinoma of the pancreas: overview of workup and management. Adv Oncol 1996;11:17-22.
21. Matsukawa Y, Semba S, Kato H, Ito A, Yanagihara K, Yokozaki H. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci 2006;97:484-91.
22. Raman JD, Mongan NP, Tickoo SK, Boorjian SA, Scherr DS, Gudas LJ. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res 2005;11:8570-6.
23. Raaphorst FM, Meijer CJ, Fieret E, et al. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia 2003;5:481-8.
24. 1-phase progression. Genes Dev 1999;13:1501-12.
25. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008;8:253-67.
26. Hu YX, Watanabe H, Li P, et al. An immunohistochemical analysis of p27 expression in human pancreatic carcinomas. Pancreas 2000;21:226-30.
27. Wei Y, Xia W, Zhang Z, et al. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog 2008;47:701-6.
28. Oshita F, Kameda Y, Nishio K, et al. Increased expression levels of cyclin-dependent kinase inhibitor p27 correlate with good responses to platinum-based chemotherapy in non-small cell lung cancer. Oncol Rep 2000;7:491-5.
29. Masciullo V, Ferrandina G, Pucci B, et al. p27Kip1 expression is associated with clinical outcome in advanced epithelial ovarian cancer: multivariate analysis. Clin Cancer Res 2000;6:4816-22.
30. Axanova L, Morré DJ, Morré DM. Growth of LNCaP cells in monoculture and coculture with osteoblasts and response to tNOX inhibitors. Cancer Lett 2005;225:35.
31. Armstrong DK, Kaufmann SH, Ottaviano YL, et al. Epidermal growth factor-mediated apoptosis of MDA-MB-468 human breast cancer cells. Cancer Res 1994;54:5280-3.